Seeking To Broaden Market For Feraheme, AMAG Runs Afoul Of DDMAC
This article was originally published in The Pink Sheet Daily
Executive Summary
The prospect of anemic Medicare compensation for Feraheme (ferumoxytol) may have pushed the company to promote the drug in ways that FDA's advertising reviewers think is illegitimate.
You may also be interested in...
DDMAC Slamming The Door On Open-Label Studies In Promotions
Nycomed gets a "notice of violation" letter for a flashcard that used open-label study data to make claims for its actinic keratoses treatment Solaraze (diclofenac).
DDMAC Slamming The Door On Open-Label Studies In Promotions
Nycomed gets a "notice of violation" letter for a flashcard that used open-label study data to make claims for its actinic keratoses treatment Solaraze (diclofenac).
Infergen Promotion Produced By Third Party Lands Kadmon In Hot Water With DDMAC
FDA's Division of Drug Marketing, Advertising and Communications cites Kadmon for failing to include risk information and overstating efficacy in a "STATgram" promoting its hepatitis C treatment interferon alfacon-1.